(firstQuint)A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma.

 This is a 52-week, open-label, multi-centre study designed to evaluate the safety of tralokinumab in a fixed 300 mg dose every 2 weeks, administered subcutaneously in adults and adolescents with indequately controlled asthma on medium to high dose inhaled corticosteroid plus long acting -2 antagonist.

 Approximately 26 Japanese subjects will be recruited to receive 22 completed.

.

 A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma@highlight

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid plus Long-Acting 2-Agonist